US life science firm Bio-Techne Corporation has announced a streamlined brand architecture designed to enable scientists and clinicians to more easily find the answers they need based on their application and stage of research including a new diagnostics brand.
The company has organised its products and technologies under three focused portfolio brands - R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics - aligning its solutions with the way modern science progresses from early discovery through translational insights to clinical diagnostics.
Bio-Techne has 50 years of history in scientific discovery and clinical innovation through a diversified portfolio of solutions: from high-quality proteins, antibodies, and small molecules to advanced technologies, including protein analytical instruments and spatial biology platforms, that enable breakthrough research.
"At Bio-Techne, our focus is empowering scientists and clinicians to achieve better answers that lead to more breakthroughs," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "By aligning our portfolio with the fast-paced progression of scientific research, we make it easier for customers to access the solutions they need to advance their work and accelerate scientific progress.”
Kelderman adds: "Our updated brand structure strengthens our position as a trusted scientific partner, bringing greater alignment across our expanding portfolio and reinforcing our mission to improve the quality of life by catalysing advances in science and medicine."
The Bio-Techne Diagnostics portfolio provides clinical laboratories and IVD manufacturers with assay kits, IVD‑grade reagents, antibodies, molecular controls, calibrators, and proficiency‑testing materials needed to design, develop, and validate reliable diagnostic assays. The portfolio supports the full lifecycle of assay development from early design through deployment at scale. By delivering high-quality raw materials and comprehensive assay solutions, Bio-Techne Diagnostics helps ensure accuracy, strengthens clinical decision‑making, and ultimately contributes to improved patient outcomes.
Bio-Techne will highlight its newly aligned portfolio at several upcoming scientific meetings, including the American Association for Cancer Research (AACR) Annual Meeting in San Diego and IMMUNOLOGY2026 in Boston, USA.